Report Overview

The global liposomal doxorubicin market was pegged at US$ 1.71 billion in 2021 and is expected to witness a CAGR of 5.4% during the forecast period.

Market Fundamentals 

Doxorubicin, a drug initially derived from the bacteria Streptomyces peucetius, was permitted for clinical use in 1974. There are numerous dosage formulations for doxorubicin, including pegylated and liposomal variations. Doxorubicin (Dox) is frequently used in medical settings to treat cancers such as multiple myeloma, Hodgkin's lymphoma, leukemias, breast cancers, bladder, stomach, ovaries, lung, and soft tissue sarcoma. The drug doxorubicin inhibits the enzymes needed for cancer cells to divide and expand. Liposomes ensure that the treatment is delivered to the cancer cells more effectively and stays in the bloodstream longer. The patient's weight, height, and overall health affect the drug's dosage. Liposomal doxorubicin has less toxicity, myelosuppression, alopecia, and nausea than other commonly prescribed medications.

[89778332]

Market Dynamics

The steep increase in cancer incidence globally is one of the main factors boosting the global liposomal doxorubicin share of the market. Over the anticipated timeframe, significant variables such as a busy lifestyle and poor eating habits that cause various health difficulties are expected to be the main drivers of liposomal doxorubicin sales. Innovations and R&D projects should open up new growth opportunities for market participants during the forecasted timeframe. The demand for liposomal doxorubicin is also anticipated to increase shortly as a result of the expansion of the healthcare infrastructure. Moreover, in the upcoming years, factors such as rising demand for targeted therapy medications, higher use of chemotherapy treatments, and increased private company investment in this application are anticipated to drive the liposomal doxorubicin market size.

Market Ecosystem

The global liposomal doxorubicin market has been analyzed from four perspectives: drug formulation, application, distribution channel, and region.

Liposomal Doxorubicin Market by Drug Formulation

[34732842]

Based on drug formulation, the global liposomal doxorubicin market has been segmented into lyophilized powder and doxorubicin injection. The market share of lyophilized powder will be more significant. Additionally, the same segment is anticipated to have the highest CAGR.

Liposomal Doxorubicin Market by Application

Based on application, the global liposomal doxorubicin market has been segmented into bladder cancer, Kaposi sarcoma, leukemia, lymphoma, breast cancer, and others. The breast cancer segment dominated the global liposomal doxorubicin market during the forecast period. One of the critical factors driving the adoption and use of the treatment for breast cancer is the growing innovation in formulations. Some factors projected to drive the market in the upcoming years are the growing need for targeted therapy medications, increased use of chemotherapy drugs, and expanding private player investment in this application.

Liposomal Doxorubicin Market by Distribution Channel

The global liposomal doxorubicin market has been segmented based on distribution channels into hospital, retail, and online pharmacies. The hospital segment accounted for the largest share during the forecast period. However, it is predicted that the retail pharmacy segment will have the fastest growth during the forecast period.

Liposomal Doxorubicin Market by Region

Based on region, the global liposomal doxorubicin market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. The liposomal doxorubicin market is dominated by North America, which holds the largest market share due to the increase in cancer cases, which is driving up the need for doxorubicin in both mono and combination chemotherapies. For instance, 11.4 per 100,000 women are diagnosed with ovarian cancer annually. Per 100,000 women annually, there were 7.0 fatalities. More than 3.1 million women in the United States had a history of breast cancer as of January 2019. Furthermore, the market in this region is expanding due to an increasing number of collaborations, mergers, and acquisitions for clinical studies using cutting-edge doxorubicin formulations.

Competitive Landscape

Some of the prominent players of the global liposomal doxorubicin market include 

• Johnson & Johnson Services, Inc.
• TTY Biopharma
• Sun Pharmaceutical Industries Ltd.
• Merck & Co.
• Cipla, Inc.
• Cadila Pharmaceuticals
• Fudan-Zhangjiang
• SRS Pharmaceuticals Pvt. Ltd.

Strategic development

• In October 2021, Padagis gained permission from the US FDA to introduce its AB-rated generic version of Doxil in collaboration with Ayana Pharma Ltd. (Doxorubicin Liposome Injection).
• In August 2021, Positive findings from the key Phase III POLARIX trial comparing Rituxan (rituximab) plus doxorubicin, cyclophosphamide, and prednisone (R-CHP) against Rituxan plus doxorubicin, cyclophosphamide, vincristine, and prednisone were announced by Genentech (R-CHOP). According to the business, the primary endpoint was reached after patients with diffuse large B-cell lymphoma who had not previously received treatment had considerably improved and clinically significant progression-free survival (DLBCL).
• In January 2019, ThermoDox Phase I TARDOX trial results were released by the oncology medication research business Celsion Corporation. The trial was conducted at the University of Oxford in the United Kingdom. ThermoDox, a patented heat-activated liposomal encapsulation of doxorubicin from Celsion, was tested in the TARBOX study combined with targeted ultrasound for treating liver cancer.

Frequently Asked Questions About This Report